Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 9/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597814 | 0.90 | PSEN1 (0.58) | CASRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4597766 | 0.88 | CASR (0.48) | CASRLMNAPSEN1PSEN2APH1B | |
| SCHEMBL4624986 | 0.87 | PSEN1 (0.60) | CASRLMNAPSEN1PSEN2APH1B | |
| SCHEMBL4597184 | 0.79 | PSEN1 (0.70) | CASRLMNAPSEN1PSEN2APH1B | |
| SCHEMBL4597252 | 0.77 | PPARD (0.60) | CASRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2846688 | 0.77 | PSEN1 (0.56) | CASRLMNAPSEN1PSEN2APH1B | |
| SCHEMBL7811140 | 0.76 | PSEN1 (0.50) | CASRLMNAPSEN1PSEN2APH1B | |
| SCHEMBL27683654 | 0.75 | GAA (0.54) | THRB | |
| SCHEMBL1202458 | 0.75 | PSEN1 (0.46) | CASRLMNAPSEN1PSEN2APH1B | |
| SCHEMBL2844382 | 0.75 | CASR (0.50) | CASRLMNAPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300261-A1 | Arylacetic Acids and Related Compounds for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2008-12-04 | — | — | US | disclosed |
| EP-1773315-B1 | ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2008-01-16 | — | — | EP | disclosed |
| EP-1773315-A1 | ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Limited (GB) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006008558-A1 | ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER’S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300261-A1 | Arylacetic Acids and Related Compounds for Treatment of Alzheimer's Disease | PSEN2, PSEN1, NAT1 | CASR 3894/4885LMNA 2620/4885PSEN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.